KRAS, TP53, CDKN2A, and SMAD4 are the most common somatic mutated genes in pancreatic cancer; 90% of patients have functional mutations in the KRAS oncogene, and 25%–80% of patients have functional mutations in TP53, CDKN2A, and SMAD4 oncogene (9–12). This evidence concerns the gene CDKN2A and pancreatic neoplasm.